Combined Effect of CYP2B6 and NAT2 Genotype on Plasma Efavirenz Exposure During Rifampin-based Antituberculosis Therapy in the STRIDE Study | Zendy

Annie Luetkemeyer | Zendy; S. Rosenkranz | Zendy; Darlene Lu | Zendy; Beatriz Grinsztejn | Zendy; Jorge Sánchez | Zendy; M. Ssemmanda | Zendy; Ian Sanne | Zendy; Helen McIlleron | Zendy; Diane V. Havlir | Zendy; David W. Haas | Zendy

Open Access

Combined Effect of CYP2B6 and NAT2 Genotype on Plasma Efavirenz Exposure During Rifampin-based Antituberculosis Therapy in the STRIDE Study

Author(s) -

Annie Luetkemeyer,

S. Rosenkranz,

Darlene Lu,

Beatriz Grinsztejn,

Jorge Sánchez,

M. Ssemmanda,

Ian Sanne,

Helen McIlleron,

Diane V. Havlir,

David W. Haas

Publication year - 2015

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/civ155

Subject(s) - efavirenz , medicine , cyp2b6 , genotype , pharmacology , calcein , virology , biology , antiretroviral therapy , human immunodeficiency virus (hiv) , genetics , viral load , gene , cyp3a4 , cytochrome p450 , metabolism , membrane

In STRIDE, slow metabolizer CYP2B6 and NAT2 genotypes were each associated with increased plasma efavirenz concentrations during antituberculosis therapy. Concentrations were greater on therapy than off therapy in 58% with CYP2B6 and 93% with NAT2 slow metabolizer genotypes. Individuals with slow metabolizer genotypes in both genes had markedly elevated concentrations.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research